Melanoma News and Research

Latest Melanoma News and Research

LAG-3 protein structure may be the key to unlocking new cancer treatments

A molecular “snapshot” of a protein can be critical to understanding its function. Scientists at Stanford and NYU have published and investigated a new structure of the protein LAG-3 which could enable the development of new cancer treatments.

11 Mar 2024

UCLA and UAMS teams secure $3.2 million NIH grant for melanoma research

A team of investigators from the UCLA Health Jonsson Comprehensive Cancer and the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute was awarded a $3.2 million grant from the National Institutes of Health to identify new ways to prevent and overcome treatment resistance to targeted therapy in patients with all sub-types of cutaneous melanoma, an aggressive form of skin cancer.

11 Mar 2024

An Arm and a Leg: The Medicare episode

Medicare may sound like an escape from the expensive world of U.S. health insurance, but it's more complicated, and expensive, than many realize.

11 Mar 2024

Study reveals key mechanism of PD-1 function

Insights into the workings of an immune cell surface receptor, called PD-1, reveal how treatments that restrict its action can potentially be strengthened to improve their anticancer effect, a new study shows.

9 Mar 2024

Inherited genetic factors may predict elevated risk of new cancers among childhood cancer survivors

Common inherited genetic factors that predict cancer risk in the general population may also predict elevated risk of new cancers among childhood cancer survivors, according to a study led by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health.

7 Mar 2024

Microbial signatures linked to immunotherapy response across cancers

The microbiome can identify those who benefit from combination immunotherapy across multiple different cancers, including rare gynecological cancers, biliary tract cancers and melanoma.

1 Mar 2024

Novel drug combination shows promise for treating advanced skin cancers in kidney transplant recipients

People who have had a kidney transplant are at high risk for developing skin cancers. New research directed by investigators from the Johns Hopkins Kimmel Cancer Center is exploring the best combination of treatments to target skin cancers while preserving the transplanted organs.

28 Feb 2024

Study reveals distinct molecular features of proximal and distal colon cancers

The colon is often thought of as one organ, but the right and left parts of the colon have different molecular features in cancers.

27 Feb 2024

Study: Antibody combination shows safety and anti-tumor activity in advanced cancer patients

In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumor activity in individuals with various types of advanced cancer.

26 Feb 2024

How did COVID-19 impact cancer incidence trends in the US?

Cancer rate patterns from March to December 2020.

23 Feb 2024

Pioneering cell-based treatment for melanoma offered at Siteman Cancer Center

Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, is one of the first centers nationwide to offer a newly approved cell-based immunotherapy that targets melanoma.

20 Feb 2024

Aging alters fibroblasts to promote pancreatic cancer growth

Older people may be at greater risk of developing pancreatic cancer and have poorer prognoses because of age-related changes in cells in the pancreas called fibroblasts, according to research led by investigators from the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins Bloomberg School of Public Health and the Bloomberg~Kimmel Institute for Cancer Immunotherapy.

20 Feb 2024

Lockdown delays in melanoma diagnosis cost Europe £6bn and thousands of lives

Delays in diagnosing melanoma due to Covid-19 lockdown may have contributed to over 100,000 years of life lost across Europe and over £6bn in costs, mainly indirectly due to loss of productivity, finds a new study led by UCL and University Hospital of Basel researchers.

16 Feb 2024

Innovative immunotherapy targets rare melanoma subtypes

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have built and demonstrated the potential efficacy of a new chimeric antigen receptor (CAR) T-cell-based immunotherapy specifically designed to treat patients with cutaneous and rare subtypes of melanoma.

16 Feb 2024

Innovative treatment increases survival of people with malignant mesothelioma, trial shows

An innovative treatment significantly increases the survival of people with malignant mesothelioma, a rare but rapidly fatal type of cancer with few effective treatment options, according to results from a clinical trial led by Queen Mary University of London.

15 Feb 2024

Phosphoproteomic profiling reveals the complex interplay of immune cells in tumors

Researchers from the Icahn School of Medicine at Mount Sinai, in collaboration with the Clinical Proteomic Tumor Analysis Consortium of the National Institutes of Health, The University of Texas MD Anderson Cancer Center, Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, and others, have unveiled a detailed understanding of immune responses in cancer, marking a significant development in the field.

14 Feb 2024

Advanced melanoma survival rates improve significantly from 2013 to 2019, Dutch study finds

The change in overall survival (OS) among advanced melanoma patients diagnosed between 2013 and 2021.

14 Feb 2024

How does melanin distribution impact UV damage?

How melanin content and distribution affect ultraviolet damage in skin.

14 Feb 2024

Androgen receptor signaling found to upregulate gene driving melanoma severity in men

Method by which androgen-activated androgen receptors (ARs) increase fucosyltransferase 4 (FUT4) expression.

12 Feb 2024

Immune cell networks key to success of personalized cancer treatment

Through an analysis of tumor samples collected over time from patients with advanced melanoma, a Ludwig Cancer Research study has identified a set of preexisting conditions in tumors that predict whether such patients are likely to respond to a personalized immunotherapy known as adoptive T cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL).

7 Feb 2024